Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - 16 days ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 2 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 6 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 10 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 10 months ago Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC - 10 months ago
2	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - 26 days ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 7 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - about 1 year ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New First-Line Option for Advanced ALK-Positive Lung Cancer - about 1 month ago FDA Approves Zanidatamab for Biliary Tract Cancer - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 4 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 5 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 11 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - about 1 year ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - 3 months ago
5	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 4 months ago FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 10 months ago Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - 11 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target - 4 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 4 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 5 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 5 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 10 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 11 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 11 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 12 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 7 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 11 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - over 1 year ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 11 months ago FDA Grants Priority Review to Repotrectinib for the Treatment of NTRK-Positive Solid Tumors - 11 months ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - 12 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - about 1 year ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - about 1 year ago

Journalists covering osimertinib